Esperion Therapeutics (ESPR)

• Market cap: $913M
• 1 day: -5.64%
• 5 days: 1.85%
• 1 month: 27.06%
• 3 months: 35.56%
• 6 months: 220.83%
• Year to date: 75%
• 1 year: 50.98%
• 5 years: -86.98%
• 10 years: -83.73%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Employees: 304